Protocol Ledger

NCT07599813 · Phase II · RECRUITING

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT07599813 sponsored by Apollo Therapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-28 Enrollment: 280 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07599813
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)280 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07599813
Protocol FieldVerified Registry Value
NCT IdentifierNCT07599813
Consolidated Lead SponsorApollo Therapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment280 participants (ESTIMATED)
Registered Start Date2026-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07599813
Hospital Research SiteLocationSite Profile
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI